SSY Group's (HKG:2005) glycerol fructose and sodium chloride injection has passed China's National Medical Products Administration's consistency evaluation of quality and efficacy of generic drugs, a Monday bourse filing said.
The injection is used mainly for the treatment of acute or chronic intracranial pressure increase and cerebral edema which are caused by cerebrovascular disease, brain trauma, brain tumors, and intracranial inflammation among other conditions.
Shares of the pharmaceutical company were down nearly 5% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments